Login / Signup

[Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 - REGATA)].

E S KropachevaO A ZemlyanskayaE N KrivosheevaE P Panchenko
Published in: Terapevticheskii arkhiv (2023)
The resumption of anticoagulant therapy after the development of major bleeding in patients with atrial fibrillation reduces the risk of thrombosis and death at a cost, while increasing the risk of recurrence of non-fatal bleeding.
Keyphrases
  • atrial fibrillation
  • venous thromboembolism
  • bone marrow
  • stem cells
  • mesenchymal stem cells